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Relationships between pathology and crystal structure in
breast calciﬁcations: an in situ X-ray diffraction study in
histological sections
Robert Scott1, Nicholas Stone2, Catherine Kendall1, Kalotina Geraki3 and Keith Rogers4
Calciﬁcations are not only one of the most important early diagnostic markers of breast cancer, but are also increasingly believed to
aggravate the proliferation of cancer cells and invasion of surrounding tissue. Moreover, this inﬂuence appears to vary with
calciﬁcation composition. Despite this, remarkably little is known about the composition and crystal structure of the most common
type of breast calciﬁcations, and how this differs between benign and malignant lesions. We sought to determine how the phase
composition and crystallographic parameters within calciﬁcations varies with pathology, using synchrotron X-ray diffraction. This is
the ﬁrst time crystallite size and lattice parameters have been measured in breast calciﬁcations, and we found that these both
parallel closely the changes in these parameters with age observed in fetal bone. We also discovered that these calciﬁcations
contain a small proportion of magnesium whitlockite, and that this proportion increases from benign to in situ to invasive cancer.
When combined with other recent evidence on the effect of magnesium on hydroxyapatite precipitation, this suggests a
mechanism explaining observations that carbonate levels within breast calciﬁcations are lower in malignant specimens.
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INTRODUCTION
Despite the central role of calciﬁcations in the early detection of
breast cancer, their pathophysiology and chemistry remain poorly
understood.1–3 This is important for two reasons:
First, there is evidence that calciﬁcations in breast cancer are
not simply passive products of the disease process, but may have
an active role in mitogenesis, upregulation of gene expression and
enhanced migration of tumor cells.1,4,5 In particular, calciﬁcations
associated with breast cancer consist predominantly of hydro-
xyapatite, and there is evidence that nanoscale properties of
hydroxyapatite may have an important role in regulating breast
cancer cell behavior.6 Understanding the nature of calciﬁcations,
and how and why they form, is important in developing a
complete picture of the factors affecting tumor development and
progression.
Second, calciﬁcation chemistry has potential for use in
diagnosis, either as an objective adjunct to conventional histo-
pathology, or by noninvasive probing, e.g., using Raman spectro-
scopy.7–9 Given that mammography screening only has a 20%
positive predictive value,10 and that in breast pathology ‘Many
gradations of normal, precancerous, and cancerous conditions are
often indistinguishable, making clear-cut diagnosis very difﬁcult
and often a cause for intense debate’,11 accurate, rapid, and
objective aids to diagnosis clearly have a role.12
For both these purposes, it is necessary to determine and
explain the relationship between calciﬁcation chemistry and
pathology. Early studies on calciﬁcations dissected from fresh
excised breast tissue revealed the presence of two distinct
chemical and crystallographic types: ‘Type I’13 are composed of
calcium oxalate dihydrate in the crystalline form of weddellite, and
are comparatively rare. The prevailing consensus is that deposition
is a feature of benign rather than malignant processes within the
breast.4,14 ‘Type II’ are much more common, and are composed of
calcium phosphates with an apatite structure. These can occur in
both benign and malignant lesions. More recent quantitative
investigations into the chemistry of Type II calciﬁcations and its
relationship with pathology have largely used Raman spectro-
scopy or FTIR (Fourier transform infrared) spectroscopy. An
important ﬁnding is that the proportion of carbonate substitution
in the hydroxyapatite lattice is higher in benign than malignant
specimens.15 Moreover, the carbonate level decreases sequentially
from benign to ductal carcinoma in situ, to invasive cancer, and in
the carcinoma specimens, carbonate substitution is negatively
correlated with histological grade.16 This ﬁnding has potential
uses in Raman discrimination of pathology.
However, there are limitations to these previous studies that
need to be addressed to progress further towards analysis of
calciﬁcation chemistry as a diagnostic tool. Although vibrational
spectroscopy gives useful information on the nature, concentra-
tion, and environment of the anions (e.g., phosphate, carbonate,
hydroxide), it gives almost no information on the cations present
(principally calcium). Any chemical characterization of calciﬁca-
tions without reference to calcium cannot be regarded as
complete.
In this study, we have sought to address these gaps by
quantitative X-ray diffraction analysis of individual calciﬁcations.
This technique gives information on the structure of the crystalline
phases comprising the calciﬁcations, which can then be related to
the pathology of the specimens. To date, X-ray diffraction of
breast calciﬁcations has been limited to a qualitative identiﬁcation
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of major phases present in small numbers of samples. There have
been no quantitative investigations of crystal lattice parameters
and peak broadening, which provide information concerning ionic
substitutions and crystallographic disorder, respectively. More-
over, investigations to date have relied on dissection of
calciﬁcations from bulk tissue specimens. Any analysis relying on
fresh tissue is hampered by the difﬁculty of accessing a wide
range of specimens. In contrast, diagnostic archives represent a
rich source of material with varying pathology, and histological
sections cut from archive blocks are readily available.
It is technically challenging to acquire spatially resolved X-ray
diffraction data of sufﬁcient quality for quantitative analysis from
the very small volumes of poorly crystalline material present in
these histological sections. To the best of our knowledge, in situ
X-ray diffraction analysis on histological sections of any sort has
only been reported twice before,17,18 in studies of vascular
calciﬁcations; this is the ﬁrst time such a technique has been
used to study breast calciﬁcations. The techniques developed
could readily be used for investigation of other pathological
calciﬁcations; similarities and differences may shed light on the
mechanisms by which these are formed.
RESULTS
Phase composition
The predominant phase in these calciﬁcations is nanocrystalline
hydroxyapatite. This is clear from Figure 1, which shows a
normalized sum of all background subtracted diffractograms,
overlaid with the theoretical peak positions for hydroxyapatite.19
In addition to the continuous Debye-Scherrer rings correspond-
ing to hydroxyapatite, discrete diffraction spots were also obser-
ved in the two-dimensional scattering patterns, indicating the
presence of a minor phase with substantially larger crystallites
than the nanocrystalline hydroxyapatite major phase. These
diffraction spots were separated from the continuous hydroxy-
apatite diffraction rings, as described in the 'Materials and
Methods' section, and the integrated diffractograms (Figure 1)
conﬁrm that this crystalline phase is whitlockite (a magnesium
substituted calcium orthophosphate with a beta-tricalcium phos-
phate structure).
The relationship between pathology and the percentage of
whitlockite within the calciﬁcations, averaged by specimen, is
shown in Figure 2. With diagnosis treated as an ordinal variable
ranked ‘benign’o ‘in situ’o ‘invasive’, the percentage of whitlock-
ite per specimen is positively correlated with diagnosis (P= 0.008
Kendall’s tau-b), i.e., the benign specimens contain the least
whitlockite and the invasive specimens contain the most.
No evidence could be found of other crystalline phases. In
particular, the scatter angle region from 29° to 30° was examined
for evidence of weddellite (calcium oxalate dihydrate) and
brushite (calcium hydrogen phosphate dihydrate), as this region
is well separated from hydroxyapatite and whitlockite peaks and
contains two major (410%) peaks each for weddellite and
brushite. In a plot of the maximum intensity over all 548
diffractograms, no peaks could be observed corresponding to
these two phases.
Hydroxyapatite analysis
The analysis of positions and widths of the intensity maxima in the
diffraction pattern gives some insight into both the ionic
substitutions in the crystal lattice and the size of the crystallites.
The hydroxyapatite crystalline domain dimensions were calcu-
lated from the ﬁtted peak widths as described in the 'Materials
and Methods' section, and are plotted in Figure 3. With the
diagnosis treated as an ordinal variable ranked ‘benign’o ‘in situ’
o ‘invasive’, the specimen mean crystallite domain ‘c’ axis length
and ‘ab’ plane domain size both showed a positive correlation
with diagnosis (P= 0.034 and P= 0.011, respectively, Kendall’s
tau-b). With diagnosis treated as a binary variable, malignant
specimens had larger ‘c’ axis length and ‘ab’ plane domain size
than benign specimens (P= 0.040 and P= 0.005, respectively,
Mann–Whitney U).
The calculated ‘a’ and ‘c’ lattice parameters of the hydroxy-
apatite phase, averaged by specimen, are plotted in Figure 4.
Figure 1. All-specimens sum diffractogram and digitally isolated
large crystallite diffractogram versus theoretical line positions and
intensities.
Figure 2. Whitlockite weight percentage average per specimen,
grouped by diagnosis. Malignant specimens contain signiﬁcantly
more whitlockite than those with a benign diagnosis. Individual
specimen details are available in Supplementary Information.
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There is a negative correlation, with a slope of ‘a’ versus ‘c’
of − 1.46 (95% conﬁdence interval: − 1.87 to − 1.05). With the
diagnosis treated as an ordinal variable, as in the domain size
analysis, the mean specimen ‘c’ lattice parameter showed a
positive correlation with diagnosis (P= 0.025, Kendall’s tau-b).
Using a binary analysis, the ‘c’ lattice parameter is larger in
malignant specimens than in benign (P= 0.019, Mann–Whitney U).
The correlation between ‘a’ lattice parameter and diagnosis was
not signiﬁcant.
Spatial variation
As the measurements were taken in uniformly spaced lines across
each calciﬁcation, the position of each measurement in the
sequence can be used to calculate an approximate proportion of
the distance from the center to the edge. The 002 FWHM (full
width half maximum) of each measurement was normalized to the
mean FWHM for that calciﬁcation, and the variation from the
center to the periphery calculated by linear regression. On
average, the 002 FWHM is 5.4% (2.6–8.2%) greater at the edge
than the center (Po0.001). This trend is very similar for benign,
in situ, and invasive specimens.
DISCUSSION
Major phases
The presence of calciﬁcations consisting predominantly of
nanocrystalline hydroxyapatite is unsurprising and concurs with
previous X-ray diffraction characterizations. Perhaps more surpris-
ingly, no ‘Type I’ calcium oxalate weddellite calciﬁcations were
observed in any of the 56 calciﬁcations analyzed. In addition, no
calcium oxalate was found in 236 calciﬁcations from 110 patients
in an FTIR study of samples taken from the same archive.16 Other
studies have reported a widely varying proportion of calcium
oxalate calciﬁcations in biopsy tissue (e.g., 0.4%,20 7.3%,14 17.3%,21
28.8% (ref. 22)). Although the specimen numbers in this pilot
study were small, the absence of calcium oxalate in these results
suggests a proportion towards the lower end of this range.
Whitlockite
The presence of whitlockite in these specimens is a novel ﬁnding.
It has occasionally been reported in other pathological calciﬁca-
tions, including prostate,23 aorta,24 cartilage,25 and salivary
glands.26 A cursory mention of a single FTIR observation in a
breast calciﬁcation with an absorption band at 990/cm consistent
with the presence of whitlockite was reported previously.27 Our
study is therefore the ﬁrst to make a positive conﬁrmation of
whitlockite in breast calciﬁcations.
The occurrence of whitlockite implies the presence of magne-
sium. Magnesium in breast calciﬁcations has previously been
reported in one study,22 with the proportion of specimens
containing magnesium increasing from benign to in situ to
invasive. This is consistent with our X-ray diffraction results
showing the least whitlockite in benign specimens, and the most
in invasive carcinoma. The presence of magnesium whitlockite is
potentially of signiﬁcance as several studies have shown that
magnesium levels both inﬂuence and are inﬂuenced by the
process of carcinogenesis.28 In particular, signiﬁcantly lowered
serum magnesium levels have been found in breast cancer
patients,28 and it has been suggested that a high Ca:Mg ratio is
risk factor in the development of postmenopausal breast cancer.29
At ﬁrst sight it is therefore surprising to ﬁnd a higher
concentration of whitlockite in calciﬁcations within malignant
specimens. However, a peculiarity of tumor cells is their avidity for
Mg, which accumulates within the cells even when extracellular
Mg concentrations are low.29 Whether calciﬁcations form from the
products of cell necrosis or through matrix vesicles,30 raised
intracellular magnesium is likely to elevate the level of magnesium
within calciﬁcations associated with breast cancer.
The observation of more magnesium whitlockite in malignant
than benign tissue specimens, together with other evidence
for higher levels of magnesium in malignant calciﬁcations,22 may
provide a clue as to why carbonate levels are lower in
calciﬁcations associated with cancer. It has recently been shown
that magnesium ions can strongly inhibit the incorporation of
carbonate in hydroxyapatite.31 Increased concentration of mag-
nesium within cancer cells could lead to higher magnesium levels
Figure 3. Hydroxyapatite crystalline domain dimensions, averaged
by specimen and categorized by diagnosis. Malignant specimens
have signiﬁcantly larger crystalline domain size in both axes than
benign specimens.
Figure 4. Hydroxyapatite lattice parameters, averaged by specimen
and categorized by diagnosis. There is a signiﬁcant negative
correlation between ‘a’ and ‘c’ lattice parameters, and the ‘c’ lattice
parameter is signiﬁcantly smaller in benign than in malignant
specimens.
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within calciﬁcations, leading in turn to lower carbonate levels in
calciﬁcations associated with breast cancer.
Precursor phases
Both brushite and OCP (octacalcium phosphate) have been
identiﬁed as precursors to the formation of hydroxyapatite in
mineralized tissue, particularly in an acidic environment,32 which is
typical of the microenvironment of solid tumors.33 No brushite
was observed in these specimens. OCP could not be distinguished
from hydroxyapatite by X-ray diffraction in this study, as the
patterns are nearly identical over the diffraction angular range
captured. The most prominent differentiating sign is the strong
low angle OCP (1 0 0) peak with a d-spacing of 19.7 Å, which does
not occur in hydroxyapatite. However, this diffraction peak occurs
considerably below the lowest angle collected in this study, and
would require a different experimental setup to detect. The
presence of OCP cannot therefore be conﬁrmed or ruled out in
these specimens.
Comparison with maturing bone
It has been suggested that the mechanisms involved in the
formation of breast calciﬁcations may be similar to those involved
in the deposition of hydroxyapatite in bone; in particular, bone
matrix proteins involved in osteoblast mineralization are also
expressed in mammary cells.30 It is therefore interesting to
compare the observed characteristics of breast calciﬁcations with
those of bone in varying stages of maturity. Calciﬁcations in
specimens with a benign diagnosis have smaller crystalline
domains, a smaller ‘c’ lattice parameter, and a larger ‘a’ lattice
parameter than specimens with in situ or invasive carcinoma.
Hydroxyapatite crystallite domain size along the ‘c’ axis in human
fetal bone has been shown to increase with increasing gestational
age, accompanied by an increase in c/a lattice parameter ratio.34
This increase in crystallite domain size dimensions continues up to
the age of about 20, also accompanied by an increase in ‘c’ lattice
parameter and decrease in ‘a’ lattice parameter.35 This combina-
tion of changes in lattice parameters and crystalline domain size
with age in both fetal and child bone parallels our observations in
breast calciﬁcations from benign to in situ to invasive. The mean ‘c’
axis domain size in benign breast calciﬁcations of 10.9 nm is
approximately equivalent to 17 week gestation fetal bone,
whereas in invasive specimens, the mean ‘c’ axis domain size of
13.7 nm is approximately equivalent to bone at 23 weeks
gestation. In addition, the mean c/a ratio of 0.728 in benign
specimens is similar to that of fetal bone at gestational age of
16 weeks, whereas in invasive specimens, the ratio of 0.730 is
similar to that of bone at 25 weeks gestation. Of course, these
similarities do not imply a temporal progression in the breast
calciﬁcations, but may reﬂect comparable differences in chemistry.
MATERIALS AND METHODS
Archive blocks
Formalin-ﬁxed parafﬁn-embedded core biopsy breast specimens were
selected from the Gloucestershire Hospitals NHS Foundation Trust
diagnostic archive (under approval from the Gloucestershire Local
Research Ethics Committee). The blocks were randomly selected from
the 2012 archive, subject to the presence of calciﬁcations in the
histopathology report, and an unambiguous classiﬁcation of ‘B2—Benign’,
‘B5a—Ductal Carcinoma In Situ’, or ‘B5b—Invasive Carcinoma’.36 For the
purposes of analysis, the specimens were also grouped as ‘Benign’ (B2)
versus ‘Malignant’ (B5a or B5b). A summary of the histopathology report
for each of the specimens analyzed is given in Supplementary Table S1.
These specimens were screened by mounting the blocks in a Nikon
Metrology XT H225 CT system and imaging at 20 kV both perpendicular
and parallel to the face of the block. Following screening, the blocks were
selected with signiﬁcant levels of calciﬁcation at or near the cut surface.
The selected blocks were then CT-scanned, and the reconstructed volumes
processed as previously described,37 to identify the position of calciﬁca-
tions relative to the tissue outlines at the surface of the blocks.
Mounting
Two sequential microtome slices of 5 μm were cut from each block. The
ﬁrst slice underwent standard H&E (hematoxylin and eosin) processing,
and was used for reference. Figure 5 shows typical H&E images of
calciﬁcations within specimens classiﬁed as B2, B5a, and B5b. The second
slice was mounted on a 12.5 μm thick polyoleﬁn heat shrink ﬁlm that was
stretched taut over a 38 mm diameter aluminum alloy ring, and held in
place with an ‘O’ ring in a groove. This ﬁlm was chosen as it only exhibits
Figure 5. H&E stained images of typical calciﬁcations: (a) Specimen
X44 (B2), (b) Specimen X53 (B5a), (c) Specimen X46 (B5b).
Histopathology summaries can be found in Supplementary Table S1.
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weak diffraction lines, which are away from peaks of interest in candidate
calciﬁcation phases. In addition, these lines are the same position as those
from the parafﬁn-embedding material.
NIST (National Institute of Standards & Technology) Standard Reference
Material 640c Silicon Powder was used for the calibration of sample–
detector distance. A slurry was made with the standard powder in a dilute
solution of PVA adhesive in distilled water, and three spots painted on the
mounting ﬁlm around and in the plane of the tissue section.
Beamline setup
The X-ray diffraction experiments were conducted on beamline I18 at
Diamond Light Source, Didcot, UK. Although in principle X-ray diffraction
measurements could have been conducted using a laboratory source,
synchrotron radiation offers substantial advantages for this type of
research. First, the high brilliance possible with synchrotron radiation
enables measurements to be made on particles such as breast
calciﬁcations, substantially quicker than even a high brightness laboratory
source. Second, instrumental broadening is typically insigniﬁcant relative
to sample broadening in this type of specimen when using synchrotron
diffraction, which minimizes a potential confounder when performing
peak-broadening analysis. Third, we wished to investigate the variation
in characteristics within individual calciﬁcations, which requires a
spatial resolution that is only realistically achievable with a microfocus
synchrotron source.
The aluminum sample rings were clamped perpendicular to the beam
on a motorized stage. Measurements were made in transmission using a
Photonic Science X-ray SCMOS camera. A video microscope was mounted
at 45° to the beam and used to position the desired point on the tissue
section in the beam. A beam spot size of 10× 10 μm was used, with an
energy of 10.0 keV. The specimen-to-detector distance was kept constant
by ensuring the center of the microscope ﬁeld of view was in focus at
maximum magniﬁcation. This was conﬁrmed by measurements on each of
the three silicon standard dots on every specimen. Calciﬁcations were
located using the video microscope, by reference to the visible tissue
outlines and the maps created from the CT measurements. The
measurements were made on typically 11 equally spaced positions in a
vertical line from the bottom to the top of each calciﬁcation. Exposure was
for 30 s per measurement. Data acquisition was performed using the
Diamond Generic Data Acquisition software, with images and ancillary
data saved in NeXus data ﬁle format. A total of 548 diffractograms were
collected from 56 discrete calciﬁcations in 15 specimens, consisting of 5
benign, 4 in situ, and 6 invasive. In addition, diffractograms were collected
for the silicon standards surrounding the specimens. These sample sizes
are sufﬁcient to achieve signiﬁcant group differences using nonparametric
testing.
Analysis
Azimuthal integration of the two-dimensional diffraction images to one-
dimensional patterns was conducted using DAWN.38 The silicon standard
images were used for calibration of beam center, detector tilt, and sample–
detector distance.
Diffractograms exhibited a large background-to-signal ratio, and it was
found beneﬁcial to subtract the background as a separate step before
pattern ﬁtting. The background was subtracted in R39 using the Peak Filling
method,40 with the background centered in the noise band. Following
background subtraction, pattern ﬁtting was conducted using TOPAS 4.2
software (BRUKER AXS).
The whitlockite diffraction spots were separated from the continuous
hydroxyapatite rings by cake-remapping in DAWN, followed by azimuthal
background subtraction and azimuthal integration at each 2θ value in R.
This is similar to a method recently proposed for the detection of abnormal
grain growth in metals.41
The average percentage of whitlockite was calculated for each specimen
from the total area of the two strongest whitlockite peaks, (0 2 10) and
(2 2 0) at 2θ≈25.05° and 27.8°, respectively, and from the total area of the
overlapping (2 1 1), (1 1 2), (3 0 0), and (2 0 2) hydroxyapatite peaks that lie
in between. Those areas were converted to weight percent using
Reference Intensity Ratios of Hydroxyapatite and whitlockite from the
ICDD PDF-2 database.42 However, it should be noted that the small
number of whitlockite crystallites in a favorable orientation in each
diffractogram will lead to inaccuracies in the relative area of each peak in
the pattern.
The hydroxyapatite crystalline domain size was calculated from the
ﬁtted FWHM of the (002), (102), (210), (211), (112), (300), (202), (310), (222),
(312), (213) peaks. A Bayesian approach was taken to decomposition of the
heavily overlapped (211), (112), (300), (202) peaks. This involved a least-
squares ﬁt using ﬁxed peak positions. These positions were calculated for
each diffractogram from the ‘a’ and ‘c’ lattice parameters from the whole
pattern ﬁt. As is typical of synchrotron measurements on this type of
material, instrumental broadening was negligible relative to the broad
diffraction peaks, and was neglected. All FWHM measurements were
converted to Integral Breadth using the Lorenzian mixing factor of the
ﬁtted pseudo-Voigt peaks, and aggregated at specimen level as a
weighted mean, using total peak area as a weight. Hydroxyapatite
crystallite shape was modeled as a cylinder with its axis in the ‘c’ direction.
The apparent coherent domain thickness in the direction of each
diffraction vector was plotted in a polar plot against the angle of the
reﬂecting plane to the crystallographic ‘c’ axis. A least-squares ﬁt line from
the Langford cylindrical model43 was ﬁtted to the data points, and the
best-ﬁt cylinder length and diameter from the model used as the
dimensions of the coherently diffracting crystallite domains.
Inhomogeneous lattice strain from ionic substitution undoubtedly also
contributes to peak broadening, and in theory it is possible to separate this
from physical size effects by Williamson–Hall or Warren–Averbach
methods. However, this is complicated by the fact that peak broadening
in this case is markedly anisotropic, and the separation of anisotropic strain
from anisotropic size effects requires data quality that is difﬁcult to achieve
with biological apatite. As a result of this, and other unaccounted sources
of peak broadening, the calculated size of the coherently diffracting
crystallite domains is bound to be smaller than the physical size of the
crystallites. Indeed, it has been suggested that bone mineral is better
described as paracrystalline, with a continuum of overlapping domains
rather than crystallites with deﬁnite crystal boundaries.44 Using coherently
diffracting domain size, uncorrected for inhomogeneous strain, ensures
comparability with the majority of studies on bone.
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